Prognostic Value of Liver Fibrotic Markers in Patients With Heart Failure
Copyright © 2023 Elsevier Inc. All rights reserved..
Several liver fibrotic markers are associated with prognosis in patients with heart failure (HF). However, the optimal markers for outcome prediction remain unclear. This study aimed to simultaneously investigate the prognostic value of liver fibrotic markers and the associations between these markers and clinical parameters in patients with HF without organic liver disease. We prospectively examined 211 consecutive patients with chronic HF between April 2018 and August 2021, excluding those with organic liver disease, using liver magnetic resonance imaging and ultrasound. A total of 7 representative liver fibrotic markers were measured in all patients. The primary outcome of interest was the composite of all-cause death and hospitalization for worsening HF. During a median follow-up period of 747 (interquartile range 465 to 1,042) days, the primary outcome occurred in 45 patients. Patients with higher hyaluronic acid and type III procollagen N-terminal peptide (P-III-P) levels showed a significantly higher incidence of the primary outcome than those without (p <0.001 and p = 0.005, respectively). The multivariable Cox regression analysis revealed that hyaluronic acid and P-III-P levels were independently associated with the risk of adverse events (hazard ratio 1.84, 95% confidence interval 1.18 to 2.87 and hazard ratio 2.89, 95% confidence interval 1.32 to 6.34, respectively) even after adjustment for a mortality prediction model, whereas the other 5 markers were not associated with the primary outcome. In conclusion, among the representative liver fibrotic markers, hyaluronic acid and P-III-P might be the optimal markers for outcome prediction in patients with HF.
| Errataetall: |
CommentIn: Am J Cardiol. 2023 Sep 15;203:500. - PMID 37532642 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
The American journal of cardiology - 200(2023) vom: 01. Aug., Seite 115-123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tada, Atsushi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9004-61-9 |
|---|
| Anmerkungen: |
Date Completed 10.07.2023 Date Revised 18.11.2023 published: Print-Electronic CommentIn: Am J Cardiol. 2023 Sep 15;203:500. - PMID 37532642 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjcard.2023.05.033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358094895 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358094895 | ||
| 003 | DE-627 | ||
| 005 | 20231226074019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjcard.2023.05.033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358094895 | ||
| 035 | |a (NLM)37307781 | ||
| 035 | |a (PII)S0002-9149(23)00330-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tada, Atsushi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic Value of Liver Fibrotic Markers in Patients With Heart Failure |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2023 | ||
| 500 | |a Date Revised 18.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Cardiol. 2023 Sep 15;203:500. - PMID 37532642 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Several liver fibrotic markers are associated with prognosis in patients with heart failure (HF). However, the optimal markers for outcome prediction remain unclear. This study aimed to simultaneously investigate the prognostic value of liver fibrotic markers and the associations between these markers and clinical parameters in patients with HF without organic liver disease. We prospectively examined 211 consecutive patients with chronic HF between April 2018 and August 2021, excluding those with organic liver disease, using liver magnetic resonance imaging and ultrasound. A total of 7 representative liver fibrotic markers were measured in all patients. The primary outcome of interest was the composite of all-cause death and hospitalization for worsening HF. During a median follow-up period of 747 (interquartile range 465 to 1,042) days, the primary outcome occurred in 45 patients. Patients with higher hyaluronic acid and type III procollagen N-terminal peptide (P-III-P) levels showed a significantly higher incidence of the primary outcome than those without (p <0.001 and p = 0.005, respectively). The multivariable Cox regression analysis revealed that hyaluronic acid and P-III-P levels were independently associated with the risk of adverse events (hazard ratio 1.84, 95% confidence interval 1.18 to 2.87 and hazard ratio 2.89, 95% confidence interval 1.32 to 6.34, respectively) even after adjustment for a mortality prediction model, whereas the other 5 markers were not associated with the primary outcome. In conclusion, among the representative liver fibrotic markers, hyaluronic acid and P-III-P might be the optimal markers for outcome prediction in patients with HF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Nagai, Toshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Yoshiya |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama-Manabe, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuneta, Satonori |e verfasserin |4 aut | |
| 700 | 1 | |a Nakai, Michikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Yasui, Yutaro |e verfasserin |4 aut | |
| 700 | 1 | |a Kazui, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Saiin, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Naito, Seiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takenaka, Sakae |e verfasserin |4 aut | |
| 700 | 1 | |a Mizuguchi, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Ishizaka, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Omote, Kazunori |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Takao |e verfasserin |4 aut | |
| 700 | 1 | |a Kamiya, Kiwamu |e verfasserin |4 aut | |
| 700 | 1 | |a Kudo, Kohsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Anzai, Toshihisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of cardiology |d 1958 |g 200(2023) vom: 01. Aug., Seite 115-123 |w (DE-627)NLM000025364 |x 1879-1913 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2023 |g day:01 |g month:08 |g pages:115-123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjcard.2023.05.033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2023 |b 01 |c 08 |h 115-123 | ||